Dáil Éireann Debate, Monday - 11 September 2023
1516. Deputy Duncan Smith asked the Minister for Health what measures are being taken to address the shortage of ADHD medications in Ireland, particularly medications such as tyvense; and if he will make a statement on the matter. [37252/23]
View answerTakeda Pharmaceuticals International AG Ireland Branch notified of shortages of a number of strengths of Tyvense (30mg, 40mg, 50mg, 60mg and 70mg) due to an unexpected increase in demand, impacting multiple global markets, not just Ireland. The company has observed a 25% global increase in demand. The company anticipates resupply of the 50mg strength on 14 September, 60mg strength on 21 September, the 30mg and 40mg strengths on 12 October and the 70mg strength on 19 October. The company has provided a letter to healthcare professionals detailing this information.
The 20mg strength of Tyvense is currently available. The company has stated that it has aligned its forecasts with the current growth trend to meet future demand. It takes some time to produce these products, and in the immediate term, the company has stated it will experience intermittent supply issues. The company has stated that it is working with wholesalers in Ireland to ensure monthly equitable distribution and prevent prolonged supply disruption.
Janssen, the company that places the Concerta XL products on the market, has informed the Health Products Regulatory Authority (HPRA) that it is encountering global supply chain issues related to component availability and increased demand in multiple markets. The company has stated that there are allocations in place to ensure equitable distribution to mitigate the impact on patients in Ireland and that it is working closely with pharmacies to ensure patients receive their medication.
At any given time, shortages of medicines can occur in any country. Increases in demand for medications and medicines shortages have been observed in the UK, throughout the EU and across the world in recent months.
Ireland has a multi-stakeholder medicine shortage framework in place, operated by the HPRA on behalf of the Department of Health. The multi-stakeholder framework includes representation from the pharmaceutical industry, healthcare professionals, the HSE, the Department of Health and patients.
Unfortunately, there are a multitude of reasons why a medicine may not be available including: shortages of raw materials; manufacturing difficulties; sudden unexpected increase in demand; or product recalls due to potential quality issues.
The HPRA publishes a list of medicines currently in short supply on its website (Medicines Shortages (hpra.ie) with the reason for the shortage and expected dates for the return of supply. The information is available to assist healthcare professionals in managing medicine shortages when they arise and reduce their impact on patients. The webpage is updated daily as the HPRA receives new information.
Any patient who is concerned regarding a medicine shortage is advised to discuss their treatment and alternative options with their doctor, pharmacist, or other healthcare professional.
